Amundi reduced its stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 10.3% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 12,342,274 shares of the company

Groupe la Francaise grew its holdings in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 254.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 260,892 shares of the company

Saudi Central Bank grew its holdings in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 22.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 440,465 shares of the company

Old Mission Investment Co LLC purchased a new stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The firm purchased 10,342 shares of the company

Three Seasons Wealth LLC boosted its stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 295.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,046 shares of the company

Maloon Powers Pitre Higgins & Dennehy LLC bought a new position in Merck & Co., Inc. (NYSE:MRK - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 6,865 shares of the company

NBH Bank purchased a new position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 10,243 shares of the company

Oakmont Investment Advisors Inc. acquired a new stake in Merck & Co., Inc. (NYSE:MRK - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 24,110 shares of the company

Merck & Co. stock is holding close to its 52-week high as investors weigh strong Keytruda sales and

TD Waterhouse Canada Inc. reduced its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 11.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 354,395 shares of the company

Burford Brothers Inc. decreased its position in Merck & Co., Inc. (NYSE:MRK - Free Report) by 78.7% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,161 shares of the company

Wells Fargo & Company boosted their price objective on Merck & Co., Inc. from $150.00 to $170.00 and gave the company an "overweight" rating in a research report on Friday.

NEOS Investment Management LLC boosted its position in Merck & Co., Inc. (NYSE:MRK - Free Report) by 11.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 404,459 shares of the company

Concurrent Investment Advisors LLC increased its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 10.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 280,871 shares of the company

Merck & Co. stock is trading near its 52-week high after Q2 2026 sales growth and a raised full-year